Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 11/2014

01-11-2014 | Prevention (L Sperling and D Gaita, Section Editors)

Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines

Authors: John Dinkler, MD, MPH, Karol Watson, MD, PhD

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 11/2014

Login to get access

Opinion statement

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Choosing the appropriate patients for whom to initiate statin therapy to reduce the risk of ASCVD is of paramount importance. The new AHA/ACC guidelines on the treatment of cholesterol emphasize a patient-centered approach that shifts away from arbitrary LDL-C goals and recommends targeting statin therapy in patient populations that show ASCVD risk-reduction benefit. In addition, the guidelines emphasize lifestyle modification and the importance of the clinician-patient relationship in discussing ASCVD risk and initiating statin therapy.
Literature
1.
Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.PubMedCrossRef
2.••
Mihaylova B, Emberson J, Blackwell L, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. One of the key meta-analyses on which the new cholesterol guidelines are based.
3.••
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1(1):CD004816. doi:10.​1002/​14651858.​CD14004816.​pub14651855. One of the key meta-analyses on which the new cholesterol guidelines are based.
4.••
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults [published online November 12, 2013]. Circulation. 2013. doi:10.​1161/​01.​cir.​0000437738.​63853.​7a. The new cholesterol guidelines in detail.
5.
Downs J, Claerfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRef
6.
Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–3207.PubMedCrossRef
7.
Ridker P, Cook N. Statins: new American guidelines for preventions of cardiovascular disease. Lancet. 2013;382:1762–5.PubMedCrossRef
8.
Cook N, Ridker P. Response to comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129:268–9.PubMedCrossRef
9.
Munter P, Colantonia LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311(14):1406–15.CrossRef
10.
Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood). 2012;31(10):2276–85.CrossRef
11.
Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65–72.CrossRef
12.
Metadata
Title
Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines
Authors
John Dinkler, MD, MPH
Karol Watson, MD, PhD
Publication date
01-11-2014
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 11/2014
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-014-0347-9

Other articles of this Issue 11/2014

Current Treatment Options in Cardiovascular Medicine 11/2014 Go to the issue

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Current Approaches to the Management of Pediatric Overweight and Obesity

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Impact of Childhood Obesity on Cardiac Structure and Function

Prevention (L Sperling and D Gaita, Section Editors)

Cardiovascular Disease Associated with the Human Immunodeficiency Virus: An Update

Pediatric Congenital Heart Disease (G Singh, Section Editor)

Childhood Obesity, Arterial Stiffness, and Prevalence and Treatment of Hypertension